Cancer Archives

News and Trends 23 Apr 2018

The First CAR-T Therapy Is Not Living Up to Commercial Expectations

Novartis’ Kymriah, the first approved CAR-T therapy worldwide, has performed far below sales expectations in the last quarter. The news highlights the challenges CAR-T therapies still face before becoming a commercially viable treatment option. CAR-T therapy has shown impressive results treating the cancer of patients for which all other treatments fail. One would expect this […]

April 23, 2018 - 3 minutesmins - By Editorial Team

News and Trends 19 Apr 2018

“This is the First Time CAR-T Has Ever Worked on Acute Myeloid Leukemia“

Celyad has reported clinical results showing the first time a patient has fully recovered from acute myeloid leukemia thanks to a CAR-T therapy, and without the need for chemotherapy preconditioning. At the AACR meeting in Chicago this week, Celyad has presented preliminary data from three of its ongoing Phase 1 clinical trials with a new […]

April 19, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

Startup Scout 13 Apr 2018

This Israeli Biotech Targets Protein Translation to Fight Disease

Today, we’re taking a look at Anima Biotech, an Israeli company that is developing a new class of drugs that target protein translation to combat a range of diseases, including lung fibrosis, cancer, and Huntington’s disease. Mission: Since 2010, Anima Biotech has been targeting disease-causing proteins with a new class of drugs that control protein translation. […]

April 13, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 11 Apr 2018

French CAR-T Developer Raises $164M Despite a Challenging Road

Cellectis has raised $164M (€132M) in a follow-on offering to further develop its CAR-T technology in clinical trials, despite having mixed results in the technology’s development up until now. Cellectis, based in Paris, has closed a follow-on offering on NASDAQ, raising a total of around $164M (€132M). The funding will be used to further continue clinical development […]

April 11, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 29 Mar 2018

Cancer Trial Halted in the UK After Overdosing First Patient

Redx Pharma has temporarily interrupted recruitment in a Phase I/IIa cancer trial following “significant adverse events” of its drug on the first patient treated. The first time Redx Pharma’s cancer drug RXC004 has been tested in a patient has resulted in adverse side effects. According to Redx, the dose tested resulted in a higher exposure […]

March 29, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 27 Mar 2018

A New Liquid Biopsy Can Improve Ovarian Cancer Diagnosis

Angle, a UK-based biotech, is developing a non-invasive liquid biopsy that could be better than current diagnostic methods at predicting ovarian cancer. Angle, a company specializing in liquid biopsies, has shown that its Pelvic Mass Triage (PMT) liquid biopsy test can differentiate between benign and cancerous pelvic masses and ovarian cysts in 95% of cases […]

March 27, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 21 Mar 2018

A Personalized Genetic Test for Breast Cancer Arrives in Europe

Agendia will launch a next-generation sequencing test in the EU to determine the chances of metastasis in breast cancer patients. Agendia, a US-Dutch biotech specializing in personalized medicine and molecular diagnostics, has obtained CE marking for the MammaPrint BluePrint Kit, a diagnostic device for breast cancer that uses next-generation sequencing technology. The kit can help clinicians identify […]

March 21, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 13 Mar 2018

Danish Biotech Collaborates With US Merck on Combination Therapy for Lung Cancer

IO Biotech will test its immune modulator in combination with Merck’s checkpoint inhibitor Keytruda, known for curing former US President Jimmy Carter’s cancer. IO Biotech, based in Copenhagen, has entered an agreement with Merck (the US one) to enter a Phase I/II trial for treating lung cancer with IO’s immune modulator, IO102, and Merck’s checkpoint […]

March 13, 2018 - 2 minutesmins - By Alexander Burik

In Depth 13 Mar 2018

The Most Important Battle in Gene Editing: CRISPR versus TALEN

Despite all the hype, CRISPR is still not in the clinic as a standalone therapy or part of another. So where is it in biotech? CRISPR needs no introduction. Since the gene editing technology first entered the spotlight in 2012 with the promise of revolutionizing gene editing, it has made headlines as the subject of a furious […]

March 13, 2018 - 6 minutesmins - By Editorial Team

News and Trends 1 Mar 2018

Could This Parisian Biotech Startup’s Cancer Treatment Compete With Merck and Novartis?

Stimunity, a Parisian biotech, secured a 2M€ seed investment to develop a cancer treatment that could compete with that of big players such as Merck and Novartis. Stimunity is a preclinical-stage startup company which develops drugs targeting a new cell signalling pathway to treat cancer. The company secured funding from Portage, a US-Canadian firm that […]

March 1, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 28 Feb 2018

Yet Another Checkpoint Inhibitor Goes to Trial with Bavarian Nordic’s Cancer Vaccine

Bavarian Nordic and AstraZeneca collaborate on a treatment that uses a cancer vaccine along with a checkpoint inhibitor to treat colorectal and pancreatic cancer. Notably, this is the third checkpoint inhibitor to be tested with Bavarian Nordic’s vaccine. A Phase I/II trial will evaluate the safety and efficacy of using Bavarian Nordic’s cancer vaccine CV301 in […]

February 28, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 21 Feb 2018

FDA Approves AstraZeneca’s Lung Cancer Treatment after Rejecting Merck and Pfizer’s

The FDA approval will give AstraZeneca a competitive advantage in the lung cancer treatment market over Merck KGaA & Pfizer, who received rejections for a similar treatment. AstraZeneca received FDA approval for Imfinzi in non-small cell lung cancer one day after Merck KgA and Pfizer received a rejection for competitor drug Bavencio in the same indication. Imfinzi (durvalumab) […]

February 21, 2018 - 2 minutesmins - By Alexander Burik

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

The First CAR-T Therapy Is Not Living Up to Commercial Expectations

“This is the First Time CAR-T Has Ever Worked on Acute Myeloid Leukemia“

This Israeli Biotech Targets Protein Translation to Fight Disease

French CAR-T Developer Raises $164M Despite a Challenging Road

Cancer Trial Halted in the UK After Overdosing First Patient

A New Liquid Biopsy Can Improve Ovarian Cancer Diagnosis

A Personalized Genetic Test for Breast Cancer Arrives in Europe

Danish Biotech Collaborates With US Merck on Combination Therapy for Lung Cancer

The Most Important Battle in Gene Editing: CRISPR versus TALEN

Could This Parisian Biotech Startup’s Cancer Treatment Compete With Merck and Novartis?

Yet Another Checkpoint Inhibitor Goes to Trial with Bavarian Nordic’s Cancer Vaccine

FDA Approves AstraZeneca’s Lung Cancer Treatment after Rejecting Merck and Pfizer’s

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!